资讯

NEWS

定了!雅培确认取消收购美艾利尔的交易!

Charlie    2016年12月09日 16:39     |  4281
来源:麦科田医疗
摘要:

本周三(12月7日)雅培正式宣布取消其收购美艾利尔的决定.

【健康点】2016年2月雅培宣布58亿美元收购美艾利尔引发业内热议,然而两家随后风波不断,先是4月份雅培以250亿美元收购了圣犹达,然后不断有关于雅培和美艾利尔之间不愉快的新闻传出,以及一系列合作出现问题传言。各种猜想在本周尘埃落定,本周三(12月7日)雅培正式宣布取消其收购美艾利尔的决定。

雅培在本周三表示,它们已经对收购美艾利尔的交易启动了终止程序,因为在雅培决定收购美艾利尔这个诊断公司十个月后,它们评估认为该公司的估值有“重大损失”。

雅培已经在特拉华法州的法院提起诉讼,要求在2017年1月下旬停止这个交易,这个交易在刚刚开始的时候价值58亿美元。

加通贝祥的Mark Massaro在接受路透社采访的时候说道:“雅培这样的安排有可能是为它未来的降价做一个铺垫。”

他同时还表示,雅培最好的策略就是创造不确定性,让美艾利尔的股票下跌,然后美艾利尔的股东便会接受一个更低的价格。而美艾利尔在周四的时候刚刚被指责其将年会延期的行为。

自从雅培和美艾利尔今年早些时候宣布交易之后,美艾利尔已经面临多重挫折,而雅培在今年四月份以250亿美元的价格收购了专注于心脏设备生产的公司圣犹达。

杰弗瑞集团的分析师Raj Denhoy说:“当美艾利尔的交易宣布之后不久,雅培作为买家便表示了很多不满和懊悔。”而两家公司之间的关系开始冷却后,美艾利尔又没有按时提交其财务报表并公开它们的账款以及海外销售情况。

今年七月,根据美国卫生监管机构的要求,美艾利尔被召回了一款用于监测血液稀释剂等级的设备,这种血液稀释剂被广泛使用,而这款监测设备被发现会得出一个错误的监测结果。在接下来的一个月,美艾利尔提起诉讼,指控雅培在反垄断意见书递交上拖沓以试图破坏交易。然后在十一月份,美艾利尔又在联邦医保业务中时没有得到报销。

雅培在本周三的时候说到,这些事态发展是史无前例的,又并不是偶然发生的孤立事件。

雅培公司外部沟通部门副总裁Scott Stoffel表示:“这种损害……只能是内部控制系统出现系统性问题的结果,加上缺乏足够的透明度,所以我们只能通过提交诉讼来解决。”

美艾利尔周三表示,雅培提出的任何申明都没有足够理由终止合并。“美艾利尔将采取一切必要的行动……迫使雅培按照其条款完成交易”该公司如是说。

在雅培发声之后,美艾利尔的股价应声下跌8%至36.67,这使得雅培每股从中受益56美元。雅培的股价下跌0.15%,报收38.48美元。

杰弗瑞集团的分析师Raj Denhoy说:“它仍然是雅培的一个良性资产。在两个公司的博弈中冷静的头脑应该会占到便宜,不过我们都只是旁观者,天知道董事会里有什么打算。”

原文链接:

Abbott Labs Has Officially Moved to Kill Its Deal to Buy Alere

Abbott Laboratories said on Wednesday that it had moved to terminate its proposed acquisition of Alere, citing a“substantial loss” in the value of the diagnostics company since they struck adeal 10 months back.

Abbott (abt) filed a complaint in the Delaware Court of Chancery to kill the deal it struck with Alere in late January, worth $5.8 billion at the time.

“This is likely posturing by Abbott to set up a scenario where a price cut could be arranged,” CanaccordGenuity’s Mark Massaro told Reuters. He said Abbott’s best bet would be to create uncertainty to drive Alere’s stock lower so the company’s shareholders would agree to a lower price. Alere alr is slated to hold its annual meeting on Thursday.

Since the two companies announced the deal, Alere has faced multiple setbacks, while Abbott in April struck a deal to buy heart devicemaker St. Jude Medical stj for $25 billion. When the Alere deal was announced, and shortly thereafter, Abbott has expressed a lot of buyers remorse, Jefferies’ analyst Raj Denhoy said.

The relationship between the two companies began to cool after Alere failed to file financial statements and disclosed probes into billing and foreign sales practices.

In July, at the behest of theU.S. health regulator, Alere recalled a device used to monitor levels of awidely used blood thinner because it was found to generate faulty results.

The following month, Alere filed a lawsuit accusing Abbott of dragging its feet on key antitrust submissions to sabotage the deal. In November, Alere lost reimbursement on its Medicare business.

These developments are unprecedented and are not isolated incidents brought on by chance, Abbott saidon Wednesday.“This damage … can only be theresult of a systemic failure of internal controls, which combined with the lack of transparency, led us to filing this complaint,” said Scott Stoffel,divisional vice president of external communications at Abbott.

Alere said on Wednesday that none of the arguments made by Abbott gave it grounds to abandon the merger.“Alere will take all actionsnecessary … to compel Abbott to complete the transaction in accordance with itsterms,” the company said.

Alere’s shares tumbled 8% to $36.67, compared with Abbott’s offer of $56 per share. Abbott’s shares were off0.15% at $38.48.

“It is still a good asset for Abbott. One would think that cooler heads should prevail, but we’re not in the boardroom,” Jefferies’ Denhoy said.

  • 0
  • 评论

    COMMENTS

    发表言论 新浪、腾讯微博帐号可直接登录
    本篇文章暂无评论

    微信公众号

    caixin-life

    财点

    Health Demo

    华大基因IPO批文下发 最快十来天可买卖股票

    还有十多天,华大基因的股票就能买卖了!

    热门标签

    TOP TAGS

    更多标签

  • 关于我们
    健康点,财新传媒旗下医疗健康新媒体,用财经视角和新媒体思路解读医疗健康产业。我们秉承财新基因,立足医疗健康,借力互联网+,关注并连接从医到药的产业力量。
    寻求报道
    若你是大健康产业的关注者、开拓者、研究者、实践者,请联系我们,健康点有兴趣报道:
    1,生命医疗、运动健身、移动健康、智能硬件的前沿资讯与热点新闻;
    2,大健康产业的新商业模式、资本故事与数据分析;
    3,身在快节奏都市却又贴近自然的生活和运动方式。

    你可以给我们发邮件:healthpoint@caixin.com